I am an expert in cancer biology, acute myeloid leukaemia (AML) and patient-derived xenograft models. I completed my PhD in red cell biology at the University of Melbourne in 2013. I then undertook a postdoctorate position at Memorial Sloan Kettering Cancer Center in New York, where I investigated mechanisms of resistance to intensive chemotherapy in patients with AML. I returned to Australia in 2017 and joined the laboratory of Prof. Andrew Wei firstly at Monash University (Australian Centre for Blood Diseases) and currently at WEHI since 2023 where I lead a translational research program. My research focus is understanding the evolution of TP53 mutated AML and resistance mechanisms to Venetoclax treatment. I have secured research funding from NHMRC and collaborate widely with industry partners including AstraZeneca, Johnson and Johnson, and Storm Therapeutics to test novel agents for therapeutic potential against AML.